For stage IIB/IIIA NSCLC, the recommended approach is which?

For stage IIB/IIIA NSCLC, the recommended approach is which?

• A. Surgery + adjuvant chemotherapy/immunotherapy and radiation
• B. Chemoradiation only
• C. Immunotherapy alone
• D. Surgery alone

Answer: (A)

In operable stage IIB/IIIA NSCLC, a multimodal plan is used to maximize long-term control: remove the tumor with surgery when feasible, then follow with systemic therapy to tackle micrometastatic disease and local-regional therapy to reduce recurrence. The surgery provides the best chance for complete local control, while adjuvant chemotherapy lowers the risk of distant relapse and improves survival. Immunotherapy given after surgery in eligible patients can further augment long-term disease control by boosting the immune response against residual cancer cells. Radiation therapy is added to improve local-regional control, especially when there are nodal involvement or margins that raise recurrence risk. So, combining surgery with adjuvant chemotherapy (and immunotherapy when appropriate) and radiation offers the most comprehensive, curative-intent approach for these stages.

In operable stage IIB/IIIA NSCLC, a multimodal plan is used to maximize long-term control: remove the tumor with surgery when feasible, then follow with systemic therapy to tackle micrometastatic disease and local-regional therapy to reduce recurrence. The surgery provides the best chance for complete local control, while adjuvant chemotherapy lowers the risk of distant relapse and improves survival. Immunotherapy given after surgery in eligible patients can further augment long-term disease control by boosting the immune response against residual cancer cells. Radiation therapy is added to improve local-regional control, especially when there are nodal involvement or margins that raise recurrence risk. So, combining surgery with adjuvant chemotherapy (and immunotherapy when appropriate) and radiation offers the most comprehensive, curative-intent approach for these stages.